Baltimore News Journal – Lifestyle
Author:
Catalytic Agency
Ascidian Completes Dose Escalation Portion of Phase 1/2 STELLAR Trial of ACDN-01 for Stargardt Disease and Announces Expanded Clinical Study Plans
May 4, 2026
Ascidian to Highlight Progress of Lead Program in Stargardt and Platform Advancements Across Therapeutic Areas at ASGCT 2026 Annual Meeting
April 28, 2026